Table 3 Vaccination status of students participating in COVID-19 serology investigation — fall academic semester 2021, Wisconsin
September | December | |||
|---|---|---|---|---|
Total participants | 223 | 100% | 172 | 100% |
Status, No. (%)a | ||||
Unvaccinated | 12 | 5.4% | 10 | 5.8% |
Partially vaccinated | 5 | 2.2% | 4 | 2.3% |
Fully vaccinated | 203 | 91.0% | 109 | 63.4% |
Boosted | 3 | 1.3% | 49 | 28.5% |
Primary series received, No. (%) | ||||
CoviShield (AstraZeneca) | 3 | 1.3% | 5 | 2.9% |
Covaxin | 0 | -- | 2 | 1.2% |
Johnson & Johnson/Janssen (J&J/Janssen) | 16 | 7.2% | 11 | 6.4% |
Moderna | 53 | 23.8% | 50 | 29.1% |
Pfizer-BioNTech | 69 | 30.9% | 72 | 41.9% |
Sinopharm (BIBP) | 29 | 13.0% | 12 | 7.0% |
Sinovac (Coronavac) | 41 | 18.4% | 10 | 5.8% |
Unvaccinated | 12 | 5.4% | 10 | 5.8% |
Detailed primary series plus booster, No. (%) | ||||
Covaxin plus J&J/Janssen | 0 | -- | 1 | 0.6% |
J&J/Janssen plus Moderna | 0 | -- | 4 | 2.3% |
J&J/Janssen plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
Moderna plus Moderna | 0 | -- | 12 | 7.0% |
Moderna plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
Pfizer-BioNTech plus Moderna | 0 | -- | 1 | 0.6% |
Pfizer-BioNTech plus Pfizer-BioNTech | 0 | -- | 23 | 13.4% |
Sinopharm plus Pfizer-BioNTech | 3 | 1.3% | 4 | 2.3% |
Sinovac plus Moderna | 0 | -- | 1 | 0.6% |
Sinovac plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
Not boosted | 220 | 98.7% | 123 | 71.5% |
Previous COVID-19 positive, No. (%) | ||||
No | 185 | 83% | 128 | 74.4% |
Yes, self-report | 32 | 14.3% | 37 | 21.5% |
Yes, based on serology but not self-reportedb | 6 | 2.7% | 7 | 4.1% |